Pontifax Venture Capital

Pontifax Venture Capital is a healthcare-dedicated venture capital firm established in 2004, focusing on groundbreaking innovations and transformative life sciences technologies across all development stages. The firm actively seeks opportunities in biotechnology, pharmaceuticals, and medical devices, aiming to address substantial unmet medical needs. With $1.2 billion under management, Pontifax has built a robust portfolio of approximately 100 companies.

The firm's foundation is rooted in the vision of its co-founder and chairman, Eli Hurvitz (1932-2011), the esteemed former CEO and chairman of Teva Pharmaceuticals. Hurvitz's legacy of fostering life sciences innovations from inception to viable operating companies continues to guide Pontifax's investment philosophy and strategic decisions today. Pontifax adopts a hands-on approach to portfolio management, actively involved in charting the course of each company, whether by establishing new ventures or partnering with existing management to nurture startups to maturity.

Pontifax's investment mandate spans early-stage to growth-stage companies, including clinical-stage enterprises. Notable investments and successful exits include companies like Kite Pharma (acquired by Gilead), cCAM Therapeutics (acquired by Merck), ArQule (acquired by Merck), Emergence (acquired by Lilly), and Prevail (acquired by Lilly). The firm has also invested in companies such as Keros Therapeutics, Ocon Healthcare, ARMGO, Abcuro, V-Wave, Graviton, Lutris Pharma, Adcytherix, Otic Pharma, EyeYon Medical, Hairstetics, ForSight Vision6, Sweetch, Agomab, and Step Pharma. Recently, Pontifax participated in the Series C financing round for Adcendo, a biotech company developing antibody-drug conjugates for cancer treatment.

The leadership team at Pontifax includes co-founder and CEO Tomer Kariv, co-founder and Managing Partner Ran Nussbaum, CFO Asaf Shinar, Ohad Hammer, Momi Karako, and Principal Lina Kaminski, PhD. This team brings diverse expertise in finance, venture capital, and life sciences, with members actively serving on the boards of numerous portfolio companies, providing strategic guidance and leveraging their extensive networks to maximize potential for success.